

Product Data Sheet

Product Name: CTCE-0214

Cat. No.: GC72196

Chemical Properties

Cas. No. 577782-52-6

Formula $C_{170}H_{254}N_{44}O_{40}$ M.Wt 3554.11

Solubility DMSO : 100 mg/mL (28.14 mM);
Need ultrasonic; Hygroscopic DMSO
has a significant impact on the
solubility of product, please use
newly opened DMSO)

Storage Store at -20°C, away from moisture
and light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the
ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or
blue ice upon request.

Structure

KPVLSYRAPFRFFGGGLKWIQEYLEKALN-NH₂ (Lactam: Lys₂₀-Glu₂₄)

Background

CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1 α (stromal cell-derived factor-1 α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

CTCE-0214 (0.01-0.1 ng/mL; 4 d) increases the expansion of CD34+ cells subsets [3].

CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF- α production[1].

CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF- α production[1].

References:

[1]. Fan H, et al. Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7.

[2]. Faber A, et al. The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 2007;2007(3):26065.

[3]. Li K, et al. Small peptide analogue of SDF-1alpha supports survival of cord blood CD34+ cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice. Stem Cells. 2006 Jan;24(1):55-64.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA